Chongqing Genrix Biopharmaceutical Co. Ltd. A (688443.SS) stock: key figures, P/E, revenue and dividend

Health Care · China · ISIN CNE100006KG8

Price
23.75 CNY
Market cap
8.71 bn CNY
P/E (2025)
–
P/S (2025)
37.74
Dividend yield
0.00 %
Net margin
-232.16 %
Return on equity (ROE)
-33.80 %
Return on assets (ROA)
-17.89 %

Chongqing Genrix Biopharmaceutical Co. Ltd. A financials

Fiscal year20242025
Revenue30.09 m CNY230.73 m CNY
Gross profit24.79 m CNY214.63 m CNY
Operating income-835.91 m CNY-545.56 m CNY
EBIT-768.38 m CNY-504.24 m CNY
Net income-797.27 m CNY-535.65 m CNY
Diluted EPS – continuing operations-2.17 CNY-1.46 CNY

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Chongqing Genrix Biopharmaceutical Co. Ltd. A

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR2302, a recombinant CD3xpMHC (HBV-S); GR2301, a recombinant anti-IL-15 monoclonal antibody; GR2304, a recombinant CD3xpMHC (PRAME); GR2502, a TCR-based antibody (TCRm); GR2603, a recombinant humanized trispecific antibody; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.